J9204 Injection mogamulizumab-kpkc, 1 milligrams
Also known as: mogamulizumab, Poteligeo
Intravenous injection of mogamulizumab-kpkc, a defucosylated humanized monoclonal antibody targeting CC chemokine receptor 4 (CCR4), dosed per 1 milligram.
In Plain Language
T-cell lymphoma-targeting antibody; immune-activating cancer therapy
Clinical Context
Used for mycosis fungoides and adult T-cell leukemia-lymphoma expressing CCR4.
RVU Information
CPT J9204 does not have a physician work RVU assigned by CMS. This is typical for supply, drug, and equipment codes — reimbursement is based on Average Sales Price (ASP), fee schedules, or payer contracts rather than the RVU system.
Billing & Documentation
J-codes represent drugs administered by a healthcare provider (not self-administered). Documentation must include the drug name, dosage, route of administration, and medical necessity. Most payers require the National Drug Code (NDC) on the claim. Bill the appropriate administration code (96365-96379) in addition to the drug code.
Specialties
Frequently Asked Questions
What is CPT code J9204?
CPT J9204 (Injection mogamulizumab-kpkc, 1 milligrams) is a J Codes (Drugs) code. Intravenous injection of mogamulizumab-kpkc, a defucosylated humanized monoclonal antibody targeting CC chemokine receptor 4 (CCR4), dosed per 1 milligram.
How is J9204 administered?
CPT J9204 is administered by a healthcare provider, typically via injection or infusion. Used for mycosis fungoides and adult T-cell leukemia-lymphoma expressing CCR4. It is used by Hematology/Oncology, Dermatology.
When is CPT J9204 used?
Used for mycosis fungoides and adult T-cell leukemia-lymphoma expressing CCR4.
Track This Code in RVU Edge
Log procedures, calculate wRVUs, and benchmark against MGMA data — all in one app.
CPT® is a registered trademark of the American Medical Association. Data sourced from CMS Physician Fee Schedule RVU26A. Descriptions, synonyms, and clinical context are original content by RVU Edge.